- Home
- GAME vs IBIO Comparison
GAME vs IBIO Comparison
Compare GAME & IBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GAME
- IBIO
- Stock Information
- Founded
- GAME 2011
- IBIO 2008
- Country
- GAME United States
- IBIO United States
- Employees
- GAME N/A
- IBIO N/A
- Industry
- GAME
- IBIO Biotechnology: Pharmaceutical Preparations
- Sector
- GAME
- IBIO Health Care
- Exchange
- GAME Nasdaq
- IBIO Nasdaq
- Market Cap
- GAME 25.8M
- IBIO 24.3M
- IPO Year
- GAME 2009
- IBIO N/A
- Fundamental
- Price
- GAME $0.90
- IBIO $3.48
- Analyst Decision
- GAME Strong Buy
- IBIO Strong Buy
- Analyst Count
- GAME 3
- IBIO 3
- Target Price
- GAME $3.67
- IBIO $4.87
- AVG Volume (30 Days)
- GAME 297.3K
- IBIO 299.1K
- Earning Date
- GAME 04-15-2025
- IBIO 02-10-2025
- Dividend Yield
- GAME N/A
- IBIO N/A
- EPS Growth
- GAME N/A
- IBIO N/A
- EPS
- GAME N/A
- IBIO N/A
- Revenue
- GAME $99,072,646.00
- IBIO $375,000.00
- Revenue This Year
- GAME $102.01
- IBIO $36.00
- Revenue Next Year
- GAME $17.88
- IBIO $33.33
- P/E Ratio
- GAME N/A
- IBIO N/A
- Revenue Growth
- GAME 210.51
- IBIO 650.00
- 52 Week Low
- GAME $0.65
- IBIO $1.05
- 52 Week High
- GAME $2.25
- IBIO $4.98
- Technical
- Relative Strength Index (RSI)
- GAME 54.66
- IBIO 55.25
- Support Level
- GAME $0.84
- IBIO $3.22
- Resistance Level
- GAME $0.95
- IBIO $3.76
- Average True Range (ATR)
- GAME 0.06
- IBIO 0.38
- MACD
- GAME 0.00
- IBIO 0.00
- Stochastic Oscillator
- GAME 62.69
- IBIO 56.41
About GAME GameSquare Holdings Inc.
GameSquare Holdings Inc is engaged to revolutionize the way brands and game publishers connect with hard-to-reach Gen Z, Gen Alpha, and Millennial audiences. Its next generation media, entertainment, and technology help creators and maximize its brand partners return on investment. Its purpose-built platform, provide marketing and creative services, offer data and analytics solutions, and amplify awareness through FaZe Clan.
About IBIO iBio Inc.
iBio Inc is a preclinical stage biotechnology company that leverages the power of Artificial Intelligence (AI) for the development of precision antibodies. CDMO. Its technology stack is designed to minimize downstream development risks by employing AI-guided epitope-steering and monoclonal antibody (mAb) optimization.